Asset Details
Do you wish to reserve the book?
Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus
Do you wish to request the book?
Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus
2025
Overview
To evaluate medical costs and resource use in patients with rheumatoid arthritis (RA) with and without diabetes mellitus (DM).
Data were obtained from the Japan Medical Data Center (JMDC) claims database. The baseline period comprised 6 months before the index date (first prescription date post-RA diagnosis) while the 12-month duration post-index date was the follow-up period. Patients with RA and DM prescribed an antidiabetic drug in the baseline period constituted the DM group, while patients with RA without DM or an antidiabetic prescription in the baseline and follow-up periods belonged to the non-DM group. Patients were matched by sex, age, Charlson Comorbidity Index (CCI), months from the first RA codes, and medications. The primary endpoint was total medical costs per patient in the follow-up period. The secondary endpoints were costs for drugs, treatments, and materials, their sub-categories, and proportions of patients using the sub-categories.
One hundred and sixty-one DM group patients and 2,974 non-DM group patients were eligible for inclusion, and 109 patients were matched from each group. The median values of age and CCI were 59 years and 2.0 in both groups. After excluding DM-specific costs, both total medical costs and drug costs were significantly higher in the DM group compared with the non-DM group (total medical costs: DM/ non-DM: 5,163 USD/ 3,782 USD, P < 0.05; drug costs: DM/ non-DM: 2,242 USD/ 1,066 USD, P < 0.05) because of a higher proportion of biological disease-modifying antirheumatic drug (DMARD) users in the DM group (DM/ non-DM: 14.7%/ 5.5%). Treatment costs and material costs did not differ between the two groups.
Medical costs for RA were higher in the DM group than in the non-DM group because of a higher proportion of biological DMARD users.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aged
/ Analysis
/ Antirheumatic Agents - economics
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Rheumatoid - complications
/ Arthritis, Rheumatoid - drug therapy
/ Arthritis, Rheumatoid - economics
/ Arthritis, Rheumatoid - epidemiology
/ Diabetes
/ Diabetes Mellitus - drug therapy
/ Diabetes Mellitus - economics
/ Diabetes Mellitus - epidemiology
/ Female
/ Humans
/ Hypoglycemic Agents - economics
/ Hypoglycemic Agents - therapeutic use
/ Male
/ Medicine and Health Sciences
/ Patients
